Head and Neck Cancer (H&N)NCT07909603
Head and Neck Cancer Strategies
An observational study of Head and Neck Cancer (H&N) and Thyroid Cancer, run by Aarhus University Hospital at 1 site in Denmark.
Trial summary
The overall aim is to investigate whether genetic and other molecular markers can improve the diagnosis, assessment of treatment response, and detection of recurrence in patients with head and neck cancer. In the longer term, the project aims to contribute to more individualised treatment strategies for our patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Head and Neck Cancer (H&N), Thyroid Cancer
- How many people
- 1,500 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Oct 2026to 31 Jul 2038
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients suspected of Head and neck cancer or thyroid cancer
Who may be able to join
- Tumor more than 1 cm in the head and neck and suspecion of cancer
Who cannot join
- Tumor too small to assure tissue for correct diangosis
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Strategies for Individualized Management of Head and Neck Cancer
The overall aim is to investigate whether genetic and other molecular markers can improve the diagnosis, assessment of treatment response, and detection of recurrence in patients with head and neck cancer. In the longer term, the project aims to contribute to more individualised treatment strategies for our patients.
The project will involve comprehensive analyses of tumour tissue and blood, including extensive genetic sequencing and other molecular profiling. Importantly, the research analyses will not have any implications for the clinical management or treatment of the individual patient included in the study.
- Conditions
- Head and Neck Cancer (H&N), Thyroid Cancer
- Keywords
- head and neck cancer, thyroid cancer, molecular markers, genetics
- Medical subject headings
- Head and Neck Neoplasms, Thyroid Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of somatic variants in head- and neck cancer based on DNA sequencing data
WGS on tumor tissue
Measured: At study inclusion (pretreatment)
Number of RNA alterations in head- and neck cancer based on RNA sequencing data
Total RNA sequencing in tumor tissue
Measured: At study inclusion (pretreatment)
Prevalence of ctDNA in blood in head- and neck cancer patients before and after treatment
WGS
Measured: At study inclusion (pretreatment), and during follow-up: 2, 6, 12, 18, 24 months after treatment
Secondary outcomes (4)
The prevalence of microbioma in tumor tissue of head and neck cancer
Sequencing analysis of bacterial DNA
Measured: At study inclusion (pretreatment)
Growth of tumormodels from head and neck cancer
Tumormodels from tumor samples from head and neck cancer patient
Measured: At study inclusion (pretreatment)
Microbioma in saliva
Sequencing analysis of bacterial DNA
Measured: At study inclusion (pretreatment), and 2 months after treatment during follow-up
Prohibition of growth of tumormodels from head and neck cancer due to phamacological inhibition: size of tumor
Tumormodels from tumor samples from head and neck cancer patient
Measured: At study inclusion (pretreatment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2026
- Study start1 Oct 2026
- Primary completion31 Jul 2033 (estimated)
- Study completion31 Jul 2038 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Head and Neck Cancer (H&N)Studies of the same condition, open and under way.
- More trials run by Aarhus University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aarhus University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07909603
- Sponsor's protocol ID
- HN-strategiesv.4
- Status last verified
- Oct 2026
- First submitted
- 7 Oct 2026
- Last updated
- 2 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Due to patient confidentiality and compliance with Danish legislation
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Strategies for Individualized Management of Head and Neck Cancer
- ClinicalTrials.gov ID
- NCT07909603
- Acronym / sponsor ID
- HN-strategiesv.4
- Conditions
- Head and Neck Cancer (H&N), Thyroid Cancer
- Keywords
- head and neck cancer, thyroid cancer, molecular markers, genetics
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- Aarhus University HospitalUniversity, hospital or other
- Study start
- 1 Oct 2026 (actual)
- Primary completion
- 31 Jul 2033 (estimated)
- Study completion
- 31 Jul 2038 (estimated)
- First posted
- 2 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall aim is to investigate whether genetic and other molecular markers can improve the diagnosis, assessment of treatment response, and detection of recurrence in patients with head and neck cancer. In the longer term, the project aims to contribute to more individualised treatment strategies for our patients.
The project will involve comprehensive analyses of tumour tissue and blood, including extensive genetic sequencing and other molecular profiling. Importantly, the research analyses will not have any implications for the clinical management or treatment of the individual patient included in the study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients suspected of Head and neck cancer or thyroid cancer
Key inclusion criteria (1 listed)
- Tumor more than 1 cm in the head and neck and suspecion of cancer
Key exclusion criteria (1 listed)
- Tumor too small to assure tissue for correct diangosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of somatic variants in head- and neck cancer based on DNA sequencing data
Time frame: At study inclusion (pretreatment)
WGS on tumor tissue
Number of RNA alterations in head- and neck cancer based on RNA sequencing data
Time frame: At study inclusion (pretreatment)
Total RNA sequencing in tumor tissue
Prevalence of ctDNA in blood in head- and neck cancer patients before and after treatment
Time frame: At study inclusion (pretreatment), and during follow-up: 2, 6, 12, 18, 24 months after treatment
WGS
4 secondary outcomes
The prevalence of microbioma in tumor tissue of head and neck cancer
Time frame: At study inclusion (pretreatment)
Growth of tumormodels from head and neck cancer
Time frame: At study inclusion (pretreatment)
Microbioma in saliva
Time frame: At study inclusion (pretreatment), and 2 months after treatment during follow-up
Prohibition of growth of tumormodels from head and neck cancer due to phamacological inhibition: size of tumor
Time frame: At study inclusion (pretreatment)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
- Individual participant dataSharing planned: Undecided. Due to patient confidentiality and compliance with Danish legislation
Related trials for Head and Neck Cancer (H&N)
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
RecruitingPhase 1/2
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
Solid Tumor, NSCLC
Not yet recruiting
Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy
Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation
Recruiting
Swallowing Rehabilitation Program for Head and Neck Tumor Patients
Head and Neck Cancer (H&N)
Active, not recruiting
Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy
Head and Neck Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Head and Neck Cancer (H&N) and Thyroid Cancer, run by Aarhus University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of somatic variants in head- and neck cancer based on DNA sequencing data (time frame: At study inclusion (pretreatment)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.